RxDoctor Payments Data

Salvatore Focella, MD

Internal Medicine · Paramus, NJNPI 1013901511

Payments from drug & device makers

$4,684in general payments, 2019–2025

Across 64 payments — averaging $73.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$697
  • Alkermes, Inc.$654
  • Neurocrine Biosciences, Inc.$602
  • AbbVie$483
  • Gilead$397
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$356
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,684 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$18,124
Medicare patients
87
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide44$48,685
JardianceEmpagliflozin51$40,403
OzempicSemaglutide15$15,376
VascepaIcosapent Ethyl18$8,699
JanuviaSitagliptin Phosphate14$7,973
XareltoRivaroxaban13$7,162
TradjentaLinagliptin11$5,545
Rosuvastatin Calcium237$3,616
Valsartan160$3,157
Nifedipine ErNifedipine105$2,875
Betaxolol Hcl40$2,358
Atorvastatin Calcium333$2,353
Bisoprolol Fumarate107$2,141
Metformin Hcl220$1,632
Metoprolol Succinate108$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$253$7,16213 claims
AbbVieSynthroid$483$49715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →